Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $89.53B | $9.04B | $3.51 |
| 2024 | $91.72B | $10.88B | $4.19 |
| 2023 | $93.35B | $11.21B | $4.23 |
| 2022 | $94.78B | $9.27B | $3.42 |
| 2021 | $87.47B | $16.91B | $6.06 |
Social Signal Score
Earnings
Thu, Feb 18(in 6 months)
Consensus estimate $2.86 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$2.75 vs $2.56beat
- Thu, Feb 19$2.71 vs $2.55beat
- Thu, Jul 24$2.48 vs $2.68miss
- Thu, Feb 13$2.59 vs $2.44beat
- Thu, Jul 25$2.79 vs $2.66beat
- Thu, Feb 22$2.74 vs $3.04miss
Estimates and results for NSRGF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NSRGF's reported EPS growth of -12.8% a year over 4 years.
- EPS in 5 years
- $1.77
- Implied price
- $40.73
- Return from $99.44
- -16.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $20.25 — -79.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -22.8% | -30.3% | -28.0% | -25.9% | -24.1% | -22.4% |
| -17.8% | -25.8% | -23.3% | -21.1% | -19.2% | -17.4% |
| -12.8% | -21.3% | -18.7% | -16.3% | -14.3% | -12.4% |
| -7.8% | -16.7% | -14.0% | -11.6% | -9.4% | -7.4% |
| -2.8% | -12.2% | -9.3% | -6.8% | -4.4% | -2.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsreuters.com·6h ago·Negative
Focus: Nestle looks to develop new products to serve users of weight-loss drugs Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy.
View source ↗